VK2809

DRUG2 trials

Sponsors

Viking Therapeutics, Inc.

Conditions

HyperlipidemiaNAFLDNASH - Nonalcoholic Steatohepatitis

Phase 2

Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

CompletedNCT02927184

Viking Therapeutics, Inc.Hyperlipidemia, NAFLD

Start: 2016-09-28End: 2019-03-26Updated: 2021-04-26

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

CompletedNCT04173065

Viking Therapeutics, Inc.NASH - Nonalcoholic Steatohepatitis

Start: 2019-11-15End: 2024-01-26Updated: 2024-06-14